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Abstract: Nephrolithiasis (NL) affects 1 in 11 individuals worldwide and causes significant patient mor-
bidity. We previously demonstrated a genetic cause of NL can be identified in 11-29% of pre-dominantly
American and European stone formers. Pakistan, which resides within the Afro-Asian stone belt, has
a high prevalence of nephrolithiasis (12%) as well as high rate of consanguinity (> 50%). We recruited
235 Pakistani subjects hospitalized for nephrolithiasis from five tertiary hospitals in the Punjab province
of Pakistan. Subjects were surveyed for age of onset, NL recurrence, and family history. We conducted
high-throughput exon sequencing of 30 NL disease genes and variant analysis to identify monogenic
causative mutations in each subject. We detected likely causative mutations in 4 of 30 disease genes,
yielding a likely molecular diagnosis in 7% (17 of 235) of NL families. Only 1 of 17 causative mutations
was identified in an autosomal recessive disease gene. 10 of the 12 detected mutations were novel mu-
tations (83%). SLC34A1 was most frequently mutated (12 of 17 solved families). We observed a higher
frequency of causative mutations in subjects with a positive NL family history (13/109, 12%) versus
those with a negative family history (4/120, 3%). Five missense SLC34A1 variants identified through
genetic analysis demonstrated defective phosphate transport. We examined the monogenic causes of NL
in a novel geographic cohort and most frequently identified dominant mutations in the sodium-phosphate
transporter SLC34A1 with functional validation.
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Nephrolithiasis (NL) affects 1 in 11 individuals worldwide and causes significant patient morbidity. We previously demon- 
strated a genetic cause of NL can be identified in 11–29% of pre-dominantly American and European stone formers. Paki- 
stan, which resides within the Afro-Asian stone belt, has a high prevalence of nephrolithiasis (12%) as well as high rate of 
consanguinity (> 50%). We recruited 235 Pakistani subjects hospitalized for nephrolithiasis from five tertiary hospitals in 
the Punjab province of Pakistan. Subjects were surveyed for age of onset, NL recurrence, and family history. We conducted 
high-throughput exon sequencing of 30 NL disease genes and variant analysis to identify monogenic causative mutations in 
each subject. We detected likely causative mutations in 4 of 30 disease genes, yielding a likely molecular diagnosis in 7% 
(17 of 235) of NL families. Only 1 of 17 causative mutations was identified in an autosomal recessive disease gene. 10 of the 
12 detected mutations were novel mutations (83%). SLC34A1 was most frequently mutated (12 of 17 solved families). We 
observed a higher frequency of causative mutations in subjects with a positive NL family history (13/109, 12%) versus those 
with a negative family history (4/120, 3%). Five missense SLC34A1 variants identified through genetic analysis demonstrated 
defective phosphate transport. We examined the monogenic causes of NL in a novel geographic cohort and most frequently 
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Nephrolithiasis (NL) affects 1 in 11 individuals during their 
lifetime (Scales et al. 2012; Tasian et al. 2015, 2016). NL 
is associated with significant patient morbidity, recurrence, 
and healthcare costs (Germino and Kirkali 2015; Rule et al. 
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2009). The causes of NL are not well understood. Until 
recently, monogenic causes of NL were thought to be lim- 
ited to rare tubulopathies and genetic syndromes. However, 
we have established that a single-gene cause of NL can be 
identifi in 11% and 16.7–29.4% of selected adult and 
pediatric stone formers, respectively (Braun et al. 2016a; 
Daga et al. 2017; Halbritter et al. 2015). These studies were 
comprised of predominantly American and European stone 
formers and, therefore, the broader relevance of these find- 
ings worldwide is not clear. 
Pakistan resides within the “Afro-Asian stone belt”, 
a region with a high prevalence of nephrolithiasis (12%) 
(Rizvi et al. 2002). Environmental risk factors, including 
chronic dehydration and nutrition, contribute to these higher 
rates of nephrolithiasis (Rizvi et al. 2002). Pakistan also has 
a high rate of consanguineous marriages (> 50%) (Romeo 
and Bittles 2014), which by nature of Mendelian genetics is 
associated with an increased prevalence of autosomal reces- 
sive genetic diseases (Overall et al. 2003). We hypothesized 
that NL disease gene mutations cause nephrolithiasis in a 
significant fraction of Pakistani stone formers. However, the 
prevalence of monogenic forms of nephrolithiasis in this 
population is unknown. 
We, therefore, performed high-throughput gene panel 
sequencing analysis of 30 known NL-causing genes in 
a cohort of 235 Pakistani subjects with nephrolithiasis 
recruited from 1 of 5 different tertiary care hospitals in Pun- 
jab, Pakistan. We show that likely causative mutations in 
known NL-causing genes are present in 7% of stone formers. 
We furthermore provide practical therapeutic and preventa- 
tive measures based on each molecular diagnosis. 
 
 




Subjects were recruited during admission for nephrolithiasis, 
which was confirmed by abdominal ultrasound. The subjects 
were admitted to one of five diff rent tertiary care hospi- 
tals in Punjab, Pakistan from July 2014 to December 2016 
(Suppl. Figure 1). Subjects received informed consent and 
provided clinical information (confirmed by their urologist 
and/or medical records), family history for pedigree con- 
struction, and a blood sample for DNA extraction. Consan- 
guinity was determined by history from adult subjects and/or 
guardians for pediatric cases by asking if parents of subjects 
were related. Ten subjects did not consent to the study, and 
seven subjects were excluded as they had an evident sec- 
ondary cause of NL (including urinary tract infections and 
secondary hyperoxaluria). Of the remaining 242 families, 
adequate DNA samples for genetic studies were obtained 
in 235 (Suppl. Figure 1). For 31 families, additional family 
members were recruited upon consent for clinical informa- 
tion and DNA submission, allowing for multi-generational 
pedigree construction. Serum chemistries, urine metabolites 
and stone analyses were requested and obtained when avail- 
able. In total, the cohort consisted of 440 individuals (235 
initial probands, 115 additional affected family members and 
90 unaffected family members) in 235 families. The study 
was approved by the institutional review board of Boston 
Children’s Hospital and the Ethical Review Committee for 
Medical and Biomedical Research, University of Health 
Sciences, Lahore, Pakistan. It adheres to the Declaration of 
Helsinki. 
 
Gene panel sequencing 
 
We performed mutation analysis using barcoded multiplex 
PCR (Fluidigm 48.48-Access Arrays™)-based approach that 
we developed previously (Braun et al. 2016a; Halbritter et al. 
2012, 2013, 2015). We designed 518 target-specifi prim- 
ers for 381 coding exons and the adjacent splice sites of 
30 genes that are known monogenic causes of nephrolithi- 
asis or nephrocalcinosis (defined by an OMIM phenotype). 
The genes screened included AGXT, APRT, ATP6V0A4, 
ATP6V1B1, CA2, CASR, CLCN5, CLCNKB, CLDN16, 
CLDN19, CYP24A1, FAM20A, GRHPR, HNF4A, HOGA1, 
HPRT1, KCNJ1, OCRL, SLC12A1, SLC22A12, SLC2A9, 
SLC26A1, SLC34A1, SLC34A3, SLC3A1, SLC4A1, SLC7A9, 
SLC9A3R1, VDR, and XDH (Suppl. Table 1). Amplicon 
sizes were chosen to range from 250 to 300 bp. Primer 
sequences will be provided upon request. The use of bar- 
coded multiplex PCR (Fluidigm 48.48-Access Arrays™ sys- 
tem) allowed parallel amplification of all 518 amplicons in 
48 patients at a time. Subsequently, the pooled libraries were 
sequenced on an Illumina MiSeq® instrument. Sequence 
reads were aligned to the human reference sequence using 
CLC Genomics Workbench™ (CLC-bio, Aarhus, Denmark) 
(Braun et al. 2016a; Halbritter et al. 2012, 2013, 2015) to 
identify variants that were distinct from the reference human 
genome (Suppl. Figure 2 and Suppl. Figure 3). We aimed 
for minimum 20 × coverage of 80% of exons in each sample 





We excluded synonymous variants and variants that occur 
with minor allele frequencies > 1% in the dbSNP (version 
147) database (Suppl. Figure 2 and Suppl. Figure 3). Vari- 
ant frequency was further assessed in exome and genome 
databases EVS, ExAC, and gnomAD of healthy control 
individuals. Remaining variants were then evaluated as in 
Suppl. Figure 2 and Suppl. Figure 3. All remaining vari- 












Odds ratios were measured using the online resource at 
MedCalc (see “Web resources”). 
 
Expression of SLC34A1 wildtype and mutant RNA 
in Xenopus laevis oocytes 
 
Animal studies adhere to the NIH guide for the Care and Use 
of Laboratory Animals or the equivalent. Xenopus laevis 
oocytes were purchased from EcoCyte and transferred to the 
standard extracellular solution for oocyte experiments con- 
taining 100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 10 mM 
HEPES, pH 7.4 adjusted with Tris. Inorganic phosphate was 
added from a 1M K2HPO4/ KH2PO4 stock premixed to give 
pH 7.4. Modified Barth’s solution for storing oocytes con- 
tained (in mM) 88 NaCl, 1 KCl, 0.41 CaCl2, 0.82 MgSO4, 
2.5 NaHCO3, 2 Ca(NO3)2, 7.5 HEPES, pH 7.5 adjusted with 
Tris and supplemented with 5 mg/l doxycyclin and 5 mg/l 
gentamicin. All standard reagents were obtained from either 
Sigma-Aldrich or Fluka (Buchs, Switzerland). Oocytes were 
injected with 50 nl of cRNA (200 ηg/µl for single injec- 
tion, 100 ng/µl total RNA for coinjection) of wildtype or 
mutant SLC34A1 constructs or water as negative control 
(NI). Constructs were designed as discussed in Supplemen- 





Water-injected control oocytes (NI), oocytes expressing 
wildtype and mutant SLC34A1 (6–8 oocytes/group) were 
first allowed to equilibrate in ND96 solution (96 mM NaCl, 
2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM Hepes, 
pH 7.4 adjusted with Tris) without tracer. After aspiration 
of this solution, oocytes were incubated in ND96 solution 
containing 1 mM cold Pi and 
32Pi (specific activity 10 mCi 
mmol-1 Pi, PerkinElmer). Uptake proceeded for 10 min, then 
oocytes were washed four times with ice-cold ND96 and 
lysed individually in 2% SDS for 30 min before the addition 
of the scintillation cocktail (Emulsifier-Safe, PerkinElmer). 
The amount of radioactivity in each oocyte was measured by 




UCSC Genome Browser, https://genome.ucsc.edu. 
Exome Variant Server, http://evs.gs.washington.edu/EVS. 
Exome Aggregation Consortium, http://exac.broadinsti 
tute.org. 
Genome Aggregation Database, http://gnomad.broadinsti 
tute.org/. 
Online Mendelian Inheritance in Man (OMIM), http:// 
www.omim.org. 
Polyphen2, http://genetics.bwh.harvard.edu/pph2. 
Sorting Intolerant from Tolerant (SIFT), http://sift.jcvi. 
org. 
MutationTaster, http://www.mutationtaster.org. 








We recruited a diverse cohort of stone formers across sex, 
age, nephrolithiasis history, and familial inheritance, as evi- 
dent from demographic data of probands from these fami- 
lies. 143 probands were male and 92 were female (M:F ratio 
1.6:1). Further clinical data were available for 229 of 235 
probands. The age of first NL episode spanned pediatric and 
adult age groups: 1–20 years, 74/229 (32%); 21–40 years, 
108/229 (47%); 41–60 years, 42/229 (18%); 61–80 years, 
5/229 (2%). The median age of onset was 28 years (range 
1–76 years). 113 (49%) of 229 probands reported a history 
of recurrent stones. 47% (109/229) of probands had a posi- 
tive family history of NL. 53% (122/229) were born from 
consanguineous unions. 
 
Monogenic causative mutation detection 
 
Using high-throughput exon sequencing of 30 NL disease 
genes in 235 subjects with renal stones, we identifi a 
molecular diagnosis in 7% (17 of 235 NL families) in 4 dif- 
ferent known NL genes SLC34A1, SLC4A1, SLC7A9, and 
APRT (Fig. 1). Panel sequencing results were confirmed by 
Sanger sequencing (Suppl. Figures 4 and 5). Heterozygous 
mutations were detected in the 3 dominant genes SLC34A1 
(12 families), SLC4A1 (3 families), SLC7A9 (1 family), 
while biallelic mutations were identified only in 1 recessive 
gene APRT (1 family) as described in Table 1 and Fig. 1. 10 
of 12 mutations (83%) were novel. Mutations in SLC34A1 
were identified in two families UF26 and UF30 where addi- 
tional family members with stones were recruited, and seg- 




We next evaluated whether molecular diagnoses correlated 
with geographic location (i.e., founder eff   and spe- 
cific clinical features. First to assess for founder mutations, 




Fig. 1  Fraction (%) of 235 Paki- 
stani NL families in whom a 
causative mutation was detected 
in 1 of 30 known NL genes 
(“solve rate”). The flow diagram 
depicts the distribution of NL 
families by solve rate and by 
mode of inheritance (recessive 
versus dominant). NL nephro- 
lithiasis. “Asterisk” indicates 
mutations in SLC34A1 deter- 
mined based on standardized 
genetic analysis and functional 







town or city where each subject lived (Fig. 2). Mutations 
were diffusely distributed through Punjab and surrounding 
provinces in Pakistan. No SLC34A1 mutations that were 
detected in multiple families clustered within specific towns 
or cities, suggesting no founder effects in our cohort. 
We next assessed for relationships between the age of 
stone onset and molecular diagnosis. To begin, we plotted 
frequency of mutation detection versus age of onset, observ- 
ing that mutation detection frequency increases with earlier 
age of onset (Fig. 3): 1–20 years, 8 of 74 (11%); 21–40 years, 
7 of 108 (7%); 41–60 years, 2 of 42 (5%); 61–80 years, 0 
of 5 (0%). 
Finally, we compared mutation detection frequency to 
history of stone recurrence, family history of stone disease, 
and parental consanguinity (Suppl. Table 2). We observed 
a higher frequency of mutation detection in subjects with 
a positive NL family history (13/109, 12%) versus those 
with a negative family history (4/120, 3%) that was statisti- 
cally significant (Suppl. Table 2). There were no correla- 
tions between the frequency of mutation detection and stone 
recurrence or consanguinity status. These analyses indicate 
that certain clinical factors such as earlier age of onset and 
family history were associated with an increased likelihood 




As SLC34A1 mutations were identifi in 12 families, we 
compared age of onset with severity of mutation (Suppl. 
Figure 6) but did not detect a clear genotype–phenotype 
relationship. 
Five of seven SLC34A1 mutations that we identified are 
novel, including four of five missense mutations (Table 1). 
SLC34A1 encodes the sodium–phosphate co-transporter 
NaPiIIa. We evaluated the impact of these mutations on 
NaPiIIa cell surface localization and phosphate transport. 
When co-expressed with wildtype SLC34A1, all missense 
mutant constructs localized appropriately on the cell sur- 
face by confocal microscopy (Suppl. Figure 7). When 
mutated SLC34A1 RNA was expressed in Xenopus oocytes, 
the fi e novel missense mutations showed defective phos- 
phate uptake in isolation (Fig. 4). An additional variant of 
unknown significance (c.365G>C; p.Ser122Thr) was identi- 
fied in family URO131 (Suppl. Table 3) but did not impair 
transporter localization or phosphate uptake (Fig. 4 and 
Suppl. Figure 7). To assess for dominant negative eff 
of our mutations, mutant SLC34A1 RNA was co-injected in 
oocytes with wildtype RNA at equimolar ratios. No mutant 
constructs suppressed phosphate transport below the activ- 
ity of oocytes expressing 50% of wildtype SLC34A1 RNA, 
suggesting these mutations do not have dominant negative 





Nephrolithiasis is a medical condition that afflicts patients 
worldwide, requiring invasive interventions and hospitaliza- 
tions, precipitating kidney injury, and leading to growing 
healthcare costs (Germino and Kirkali 2015; Scales et al. 
2012). We have previously demonstrated that a single-gene 
cause can be identifi in 11–29% of cases depending on 
age of onset (Braun et al. 2016a; Daga et al. 2017; Halbritter 
et al. 2015). However, these previous fi were based 
on cohorts primarily recruited from the United States and 
Europe. 
Here, we performed mutational analysis in a large 
cohort of Pakistani stone formers with nephrolithiasis at 
presentation and provide the first large-scale evaluation of 
monogenic stone disease in the Afro-Asian stone belt. We 
sequenced the coding regions of 30 established NL disease 
genes and identified the likely causative mutation in 17 of 
Multiplex PCR sequencing of 
30 known NL genes in 235 
families 
Families solved for known 
NL genes: 
17 (7%) 




16/17 families (94%) 
[SLC34A1*, SLC4A1 SLC7A9] 
Recessive mutations: 











Table 1  Molecular genetic diagnoses established in 3 dominant genes in 20 individuals from 16 NL families (6.8%) and in 1 recessive gene in 1 family (0.4%) out of 235 families with NL from 
Punjab province in Pakistan 
Family_Individual  Nucleotide change  Amino acid 
change 





















SLC34A1 (type 2 sodium–phosphate cotransporter) 
 
UF26-2 c.511G > A p.Val171Ile het 0.881, D r. 1/37/276,942 Novel F 35 Yes Y Y NL 
UF26-3 c.511G > A p.Val171Ile het 0.881, D r. 1/37/276,942 Novel M 30 No   NL 
UF26-4 c.511G > A p.Val171Ile het 0.881, D r. 1/37/276,942 Novel M 20 Yes   NL 
UF30-3 c.653C > T p.Ala218Val het 0.899, C i. 0/23/276,526 Novel M 22 No Y Y CaOx NL 
UF30-4 c.653C > T p.Ala218Val het 0.899, C i. 0/23/276,526 Novel F 30 No   NL 
URO-11 c.652G > A p.Ala218Thr het 0.784, C i. 2/100/276,574 Novel M 25 Yes Y Y NL 
URO-12 c.398C > T p.Ala133Val het 0.991, C.i. 3/1003/277,188 Y F 55 Yes N N NL 
URO-13 c.1225G > A p.Gly409Ser het 0.999, C.e. 0/27/246,234 Novel M 17 No Y Y NL 
URO-17 c.293dup p.Ala99Argfs*37 het NA NP Novel M 18 No N Y NL 
URO-29 c.398C > T p.Ala133Val het 0.991, C.i. 3/1003/277,188 Y M 40 Yes Y Y NL 
URO-88 c.293dup p.Ala99Argfs*37 het NA NP Novel M 40 Yes N N NL 
URO-117 c.1006 + 1G > A Splice site het NA 0/16/246,190 Y F 17 No Y Y NL 
URO-133 c.398C > T p.Ala133Val het 0.991, C.i. 3/1003/277,188 Y M 8 Yes N Y CaOx NL 
URO-140 c.1006 + 1G > A Splice site het NA 0/16/246,190 Y M 36 Yes Y N NL 
URO-169 c.398C > T p.Ala133Val het 0.991, C.i. 3/1003/277,188 Y M 52 Yes Y N NL 
SLC4A1 [anion exchanger (Diego blood group)] 
 
URO-35 c.286C > T p.Arg96Cys het 0.838, M.m. 0/73/246,164 Novel F 20 No Y N NL 
URO-178 c.911G > A p.Arg304Gln het 0.752, X.t 0/23/237,418 Novel M 1 No N Y NL 
URO-196 c.1541G > C p.Arg514Pro het 0.948, C.i. 0/1/30,782 Novel F 40 No Y N NL 
SLC7A9 [solute carrier family 7 (glycoprotein-associated amino acid transporter light chain, bo,+ system), member 9] 
URO-152 c.1076_1077dup p.Ile360Valfs*3 het NA NP Novel  M 24 No Y N NL 
Recessive gene 
APRT (adenine phosphoribosyltransferase) 
URO-77 c.292_293del p.Trp98Glyfs*11 Hom NA NP Novel  M 3 No Y Y NL 
 
 
CaOx calcium oxalate; C.e. Caenorhabditis elegans; D.r. Danio rerio; F female; het heterozygous; Hom homozygous; M male; M.m. Mus musculus; N no; NA not applicable; ND No data; NL 
nephrolithiasis; NP not present; PPh2 Polyphen2-HumVar (http://genetics.bwh.harvard.edu/pph2/); X.t. Xenopus tropicalis; Y yes 







Fig. 2 Regional distribution of 12 different mutations in 4 known 
NL genes (SLC34A1, SLC4A1, SLC7A9, APRT) detected in NL 
families in Punjab and 2 neighboring provinces of Pakistan. The 
SLC34A1 mutations p.Ala99Argfs*37, c.1006+1G>A, p.Ala218Val 
and p.Ala133Val were observed in multiple families (2, 2, 2, and 4, 
respectively) but did not aggregate within sub-regions of Pakistan, 
suggesting these are not founder alleles 
 
 
235 (7%). This study confirms our previous findings (Braun 
et al. 2016a; Daga et al. 2017; Halbritter et al. 2015) that 
mutations in NL disease genes can explain a substantial frac- 
tion of disease in stone forming individuals. 
We detected a causative mutation more frequently in those 
with a positive family history of NL than those lacking a 
family history of NL (Suppl. Table 2), which was reported in 
renal stone disease previously (Halbritter et al. 2015; Stech- 
man Michael et al. 2007). This finding is consistent with a 
vertical pattern of inheritance, which we would expect from 
the mainly dominant mutations identified in our cohort. We 
also identified a causative mutation more frequently in those 
with early age of onset relative to those with later age of 
onset, consistent with previous studies (Braun et al. 2016a; 
Daga et al. 2017; Halbritter et al. 2015). In future studies, 
it will be important to consider these genetic diagnoses in 
correlation with additional clinical presenting factors and 
biomarkers that impact patient management including stone 
analysis, serum chemistries and urine metabolite studies. 
The frequency of causative mutations in Pakistani 
stone formers overall was lower than previously observed 
in Halbritter et al. 2015 (7.2% here versus 15%). Both 
studies had similar percentages of pediatric cases (32% in 
this study versus 36%), which should not, therefore, bias 
mutation detection. Diff rences in the genetic landscape 
of Pakistani stone formers versus other populations may 
also contribute. Moreover, “unsolved” Pakistani subjects 
may have mutations in novel NL genes not yet identifi 
from other populations or copy number variants (dele- 
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The most frequently mutated gene in our cohort was 
SLC34A1, which encodes the proximal tubule sodium–phos- 
phate co-transporter NaPiIIa (Schlingmann et al. 2016). 
Recessive SLC34A1 mutations in humans cause infantile 
 
Although more controversial, dominant mutations have 
been identified in subjects with NL or nephrocalcinosis and 
 
et al. 2016a; Daga et al. 2017; Fearn et al. 2018; Halbritter 
et al. 2015; Prié et al. 2002; Rajagopal et al. 2014; Schling- 
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Fig. 3 Distribution of age of onset in NL families in whom a causa- 
tive mutation was detected in three dominant and one recessive gene. 
Frequency of subjects solved for causative mutations in one of the 
known NL genes is binned across ages of onset. Note that genetic 
diagnoses are most frequent during the first 2 decades of life. Relative 
frequencies of “solved” versus “unsolved” cases were 1–20 years, 8 
of 74 (11%); 21–40 years, 7 of 108 (7%); 41–60 years, 2 of 42 (5%); 





























Fig. 4 Effect of Pakistani stone former SLC34A1 mutations on PO4 
transport. Uptake of radioactively labeled phosphate was measured in 
Xenopus laevis oocytes upon injection with SLC34A1 wildtype and 
mutant RNA or water as a control. Level of uptake was normalized 
as a percent of wildtype SLC34A1. The above histogram represents 
the mean of three experiments with standard error of the mean shown 
by error bars. Asterisk indicates statistically significant difference 




Alternatively, environmental factors such as chronic dehy- 
dration could have a more prevalent role in NL pathogen- 
esis in Pakistan, increasing stone risk suffi y in those 
lacking a monogenic cause (Rizvi et al. 2002). 
mann et al. 2016). Our current study adds 5 novel SLC34A1 
mutations and 12 novel families with dominant SLC34A1 
NL disease to the previous 9 mutations and 10 families in the 
literature (Braun et al. 2016a; Daga et al. 2017; Fearn et al. 
2018; Halbritter et al. 2015; Prié et al. 2002; Rajagopal et al. 
2014; Schlingmann et al. 2016). The age of onset did not 
correlate with mutation severity and, in fact, varied within 
families with segregating heterozygous SLC34A1 mutations 
(Suppl. Figure 6, Table 1). This suggests that other factors 
(e.g., environmental triggers including diet) likely influence 
the age-related penetrance of these mutations. 
Importantly, the fi e missense mutations in our cohort 
were functionally validated and harbor defective phosphate 
uptake activity (Fig. 4) although not through dominant-nega- 
tive effects on the wildtype protein (Suppl. Figure 8). Studies 
of Slc34a1 knockout mice suggest that dominant SLC34A1 
mutations may rather cause stone disease through haploin- 
sufficiency (Beck et al. 1998). Heterozygous null Slc34a1 
knockout mice display abnormalities in calcium/phosphate 
homeostasis that increase NL risk including increased phos- 
phate excretion and elevated 1,25-(OH)2 vitamin D3 levels 
(Prié et al. 2001). 
In our previous studies of consanguineous families with 
NL or other renal disease, we have identifi autosomal 
recessive mutations in known disease genes in a substantial 
fraction of cases (Braun et al. 2016a, b; Daga et al. 2017; 
Halbritter et al. 2015; Sadowski et al. 2015; Warejko et al. 
2018). We were, therefore, surprised to identify a recessive 
cause of NL only once (0.4%) in this cohort despite the 
high frequency of Pakistani subject consanguinity (Suppl. 
Table 2). Because of the high degree of consanguinity, NL 
disease in Pakistani families may exhibit more complex 
genetic inheritance patterns, as was observed previously 
with limb–girdle muscular dystrophy on Réunion Island 
(Beckmann 1996; Richard et al. 1995): single families may 
have multiple distinct recessive and/or dominant causative 
mutations, hampering monogenic mutation detection. 
Another explanation is that the current cohort and our 
previous NL studies ascertained different forms of NL dis- 
ease. The Pakistani NL subjects were uniformly recruited 
during hospitalization under the care of an expert urolo- 
gist for a nephrolithiasis episode. In our previous reports, 
subjects were also recruited by nephrologists in specialty 






















































































































clinics and, in some cases, presented with broader and more 
severe clinical features in addition to NL such as failure to 
thrive, chronic kidney disease, acid–base disturbances, and 
electrolyte abnormalities (Braun et al. 2016a; Daga et al. 
2017; Halbritter et al. 2015). The latter severe cases may, 
therefore, have distinct genetic etiologies (i.e., mutations in 
known recessive NL genes) from our Pakistani subjects with 
isolated NL. 
Identifying the monogenic etiology in patients with neph- 
rolithiasis can provide additional preventative, diagnostic, 
and therapeutic implications in concert with standard clini- 
cal diagnostics such as stone analysis and urine metabolite 
studies that currently guide patient care. For instance, in 
subject URO-77 bearing a recessive truncation mutation in 
APRT (Table 1, Supplementary Table 4), allopurinol therapy 
should be initiated to stabilize and/or improve renal function. 
Despite the declining costs of genetic testing, genetic diag- 
nostics may not be economically feasible for all patients in 
resource-limited settings such as Pakistan. Until genetic test- 
ing becomes more financially viable in these settings, it may 
be most relevant to cases with severe onset (i.e., early age, 
renal dysfunction), with strong family history, and where 





We examined the monogenic causes of NL in a novel geo- 
graphic cohort and most frequently identifi dominant 
mutations in the sodium–phosphate transporter SLC34A1 
with functional validation. 
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Supplementary Methods 1 
Preparation of Plasmid Constructs/Mutagenesis 
To study the expression of wildtype and mutant SLC34A1 in mammalian cells, 
SLC34A1 constructs were fused at the c-terminus to EGFP by subcloning the cDNAs 
into the pEGFP-C1 vector (Clontech) or RFP (kindly provided by Andreas Werner). 
Missense mutations identified in Pakistani stone formers (Table 1) were introduced 
into SLC34A1-RFP constructs by site-directed mutagenesis using the QuickChange II 
kit (Agilent). Mutagenic primers were designed using the Agilent web based 
QuickChange® Primer Design software Program. XL1-Blue ultracompetent cells were 
transformed with the PCR products from the site-directed mutagenesis. The plasmids 
containing the generated mutations were isolated using QIAprep Spin Miniprep 
(Qiagen, 27106) and all mutations were confirmed by sequencing (Microsynth). One 
clone from each construct was used for the experiments. 
PCR templates used for cRNA synthesis were generated by specific primers 
introducing T3 promoter sequence upstream of the starting ATG of SLC34A1, EGFP 
or RFP respectively at the 5’ end and a 3’ primer maintaining the SV40 polyA terminator 
signal. 
Primers 5'-3' 













Sequence of PCR products were confirmed by sequencing (Microsynth). For 
heterologous expression in Xenopus laevis oocytes, capped cRNA was synthesized in 
vitro using Megascript T3 kit (Ambion) in the presence of cap analog (New England 
Biolabs).  
Cell culture and transient transfections 
Opossum kidney cells (clone 3B/2) were cultured in DMEM / Ham's F-12 medium (1:1) 
supplemented with 10% fetal calf serum, 2 mM glutamine, 20 mM HEPES and 50 IU/ml 
penicillin/streptomycin. Cells were plated on coverslips in 12 multiwell plates (TPP), 
and cultures were transfected with either wildtype SLC34A1-EGFP and wildtype or 
28 
 
mutant SLC34A1-RFP. Cultures were transfected at 70% confluency by an overnight 
incubation in 500 µl OPTIMEM (GIBCO, 31985-047) containing 1 μg of DNA and 3 μl 
of Lipofectamine™ 2000 Reagent (Invitrogen, 11668-019). We performed two 
independent experiments, each in duplicates or triplicates. 
Actin staining and confocal microscopy  
Upon expression of clear patches of wildtype SLC34A1 signal (2-3 days after 
transfection), cells were fixed and permeabilized with saponin. Thereafter, actin was 
stained by incubation with Alexa Fluor™ 647 Phalloidin (Invitrogen) diluted 1:500. After 
incubation for 30 min in the dark, cells were washed three times with PBS/saponin and 
once with PBS. The coverslips were then mounted on microscope slides using Dako 
Glycergel® Mounting Medium. The subcellular final locations of the transfected 
cotransporters were analyzed by Confocal Laser Scanning Microscopy (Leica SP2) 
using a 63X oil immersion objective at the Center for Microscopy and Image Analysis 
at the University of Zurich. 
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Supplementary Table 1. Thirty genes that are known to cause monogenic forms of NL/NC and that were included in this study. 
 Gene 
Symbol 







1 AGXT Alanine-glyoxylate aminotransferase NM_000030.2 Primary hyperoxaluria, type 1 259900 AR 11 1 
2 APRT Adenine phosphoribosyltransferase NM_000485.2 
Adenine phosphoribosyltransferase 
deficiency, 
Urolithiasis (DHA stones), renal 
failure 
614723 AR 5 2 
3 ATP6V0A4 
ATPase, H+ transporting, lysosomal 
V0 subunit a4 
NM_020632.2 dRTA 602722 AR 20 3 
4 ATP6V1B1 
ATPase, H+ transporting, lysosomal 
56/58kDa, V1 subunit B1 
NM_001692.3 
Distal renal tubular acidosis (dRTA) 
with deafness 
267300 AR 14 4 
5 CA2 Carbonic anhydrase II NM_000067.2 Osteopetrosis + d/pRTA 259730 AR 7 5 
6 CASR Calcium-sensing receptor NM_001178065.1 
Hypocalcemia with Bartter syndrome 
/ 
hypocalcemia, autosomal dominant 
601198 AD 6 6 
7 CLCN5 Chloride channel, voltage-sensitive 5 NM_001127898.3 




XR 14 7 
8 CLCNKB 
Chloride channel, voltage-sensitive 
Kb 
NM_000085.4 Bartter syndrome, type 3 607364 AR 19 8 
9 CLDN16 Claudin 16 NM_006580.3 
Familial hypomagnesemia with 
hypercalciuria & 
nephrocalcinosis (FHHNC) 
248250 AR 5 9 
10 CLDN19 Claudin 19 NM_001123395.1 
Familial hypomagnesemia with 
hypercalciuria & 
nephrocalcinosis (FHHNC) with 
ocular abnormalities 
248190 AR 4 10 
11 CYP24A1 
Cytochrome P450, family 24, 
subfamily A, polypeptide 1 
NM_000782.4 
1,25-(OH) vitamin D-24 hydroxylase 
deficiency, infantile hypercalcemia 
143880 AR 11 11 
12 FAM20A 




amelogenesis imperfect and 
nephrocalcinosis 





NM_012203.1 Primary hyperoxaluria, type 2 260000 AR 9 13 
14 HNF4A Hepatocyte nuclear factor 4, alpha NM_000457.4 
Mature onset diabetes of the young 
Fanconi syndrome + 
Nephrocalcinosis 
125850 AD 1 14 





Kelley-Seegmiller syndrome, partial 
HPRT  
deficiency, HPRT-related gout 
300323 XR 9 16 
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17 KCNJ1 
Potassium inwardly-rectifying 
channel, subfamily J, member 1 
NM_000220.4 Bartter syndrome, type 2 241200 AR 2 17 
18 OCRL Oculocerebrorenal syndrome of Lowe NM_000276.3 Lowe syndrome / Dent disease 2 
309000 / 
300555 
XR 24 18 
19 SLC12A1 Solute carrier family 12, member 1 NM_000338.2 Bartter syndrome, type 1 601678 AR 27 19 
20 SLC22A12 
Solute carrier family 22 (organic 
anion/urate transporter), member 12 
NM_144585.3 Renal hypouricemia, RHUC1 220150 AR/AD 10 20 
21 SLC26A1 
Solute carrier family 26 (sulfate 
transporter), member 1 
NM_213613 Nephrolithiasis, calcium oxalate 167030 AR 4 21 
22 SLC2A9 
Solute carrier family 2 (facilitated 
glucose transporter), member 9 
NM_001001290.1 Renal hypouricemia, RHUC2 612076 AR/AD 13 22 
23 SLC34A1 
Solute carrier family 34 (sodium 








AR/AD 13 23 
24 SLC34A3 
Solute carrier family 34 (sodium 
phosphate), member 3 
NM_001177316.1 
Hypophosphatemic rickets with 
hypercalciuria 
241530 AR 12 24 
25 SLC3A1 
Solute carrier family 3 (cystine, 
dibasic and neutral amino acid 
transporters, activator of cystine, 
dibasic and neutral amino acid 
transport), member 1 
NM_000341.3 Cystinuria, type A 220100 AR 10 25 
26 SLC4A1 
Solute carrier family 4, anion 
exchanger, member 1 (erythrocyte 
membrane 
protein band 3, Diego blood group) 
NM_000342.3 
Primary distal renal tubular acidosis, 
dominant / recessive 
179800 / 
611590 
AR/AD 19 26 
27 SLC7A9 
Solute carrier family 7 (glycoprotein 
associated 
amino acid transporter light 
chain, bo,+ system), member 9 
NM_014270.4 Cystinuria, type B 220100 AR/AD 12 27 
28 SLC9A3R1 
Solute carrier family 9, subfamily A 
(NHE3, cation proton antiporter 3), 





612287 AD 6 28 
29 VDR 
Vitamin D (1,25- dihydroxyvitamin 
D3) receptor 
NM_000376.2 Idiopathic hypercalciuria 277440 AD 11 29 
30 XDH Xanthine dehydrogenase NM_000379.3 Xanthinuria, type 1 278300 AR 36 30 
AD, autosomal dominant; AR, autosomal recessive. 
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Supplementary Table 2A. Mutation detection frequency versus stone recurrence status in 
probands of 229 NL families*. 
 Detection of causative mutation 
Subject with stone 
recurrence 
Yes (% Total) No Total 
Yes 8 (8%) 105 113 
No 9 (8%) 107 116 
Total 17 212 229 
Odds Ratio 0.91 (95% CI 0.34-2.4), p = 0.84 
*No data for 6 families. 
 
Supplementary Table 2B. Mutation detection frequency versus positive family history in 229 
NL families*. 
 Detection of causative mutation 
Positive Family 
History 
Yes (% Total) No Total 
Yes 13 (12%) 96 109 
No 4 (3%) 116 120 
Total 17 212 229 
Odds Ratio 3.9 (95% CI 1.2-12.4), p = 0.02  
*No data for 6 families. 
 
Supplementary Table 2C. Mutation detection frequency versus reported consanguinity status 
in 229 NL families*. 
 Detection of causative mutation 
Subject with reported 
consanguinity 
Yes (% Total) No Total 
Yes 10 (8%) 112 122 
No 7 (7%) 100 107 
Total 17 212 229 
Odds Ratio 1.28 (95% CI 0.47-3.5), p = 0.6344 










Supplementary Table 3. Variant of unknown significance in SLC34A1 in 1 family (0.4%) out of 235 families with NL from Punjab 





























SLC34A1 [Type 2 sodium/phosphate cotransporter]; Nephrolithiasis/osteoporosis, hypophosphatemic, 1 
URO-131 c.365G>C p.Ser122Thr het 0.965, C.e. NP Novel M 45 Yes N Y NL 
C.e., Caenorhabditis elegans; het, heterozygous; M, male; N, no; NA, not applicable; NL, nephrolithiasis; NP, not present; PPh2, Polyphen2-HumVar 




Supplemental Table 2: Clinical implications following detection of a monogenic cause of NL/NC. 

















1. Genetic counseling  







1. Genetic counseling 
2. Screen for hemolytic anemia 
3. Screen for urine acidification defects 
4. Screen for acidemia, hypokalemia, and hypocalcemia. 
5. Screen for bone mineralization disease.  
 
SLC7A9 
  URO-152 
 
1. Genetic counseling 
2. Measure urine cystine levels 
3. Consider alkalinization and pencillamine therapies.  
 
APRT 
  URO-77 
 
1. Genetic counseling 
2. Allopurinol therapy 
 
NC, nephrocalcinosis; NL, nephrolithiasis.  
259 families with a
diagnosis of at least one
renal stone by abdominal
ultrasound approached at
urology units of 5 tertiary
care hospitals in Pakistan




• 7 families with 
potential secondary 
causes of NL
• 10 families refused 
to consent to study 
and/or provide 
blood sample
235 families underwent 
High Throughput Gene 
Panel Sequencing for 30 
known NL genes 
Supplementary Figure 1. Patient recruitment and sequencing workflow. Genomic DNA from
235 families (350 affected patients) with a clinical diagnosis of NL were sequenced for causative
mutations in 30 known genes that cause NL, using barcoded multiplex chain reactions and next
generation sequencing approach4,5.
Inadequate DNA 
sample for analysis in 
7 families
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Supplementary Figure 2. Schematic view of the variant filtering pipeline implemented for
the identification of known gene mutations resulting in NL phenotype.
I. Keep non-synonymous variants and intronic variants that are located within splice sites.
II. Keep rare variants present with minor allele frequency (MAF) <1% in healthy control cohorts
dbSNP147 (https://www.ncbi.nlm.nih.gov/projects/SNP).
III. Applying known gene approach by selecting all variants detected in known nephrolithiasis genes
(Suppl. Table 1).
IV. Ranking of remaining variants based on their predicted likelihood to be deleterious for the function of
the encoded protein using Polyphen 2 (http://genetics.bwh.harvard.edu/pph2, SIFT
(http://sift.jcvi.org/) and Mutation Taster (http://www.mutationtaster.org)
V. Reviewing literature and review with referring physician delineating whether the detected mutation
matches the phenotype.
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Include homozygous or compound heterozygous alleles as disease causing if:
• Truncating mutation (stop, abrogation of start or stop, obligatory splice, frameshift) or
• Missense mutation if any of following criteria were met:
• Predicted deleterious for the protein function (at least in two among three prediction
programs (Polyphen (>0.5), SIFT (Del.), Mutation taster (D.C.))
• Continuously conserved at least among vertebrates (or beyond)
• Previously reported as disease causing with functional evidence implicating mutation
causality
Exclude allele as disease causing if:
• Allele frequency
• Allele frequency >1% (in EVS server, ExAC, gnomAD, 1000 genomes)
• Non segregation
• if compound heterozygous variants are in cis or if an affected family member is without
the variant or an unaffected family members is with the variant
Discussion of genotype-phenotype correlation in a panel of nephro-geneticists followed by
review of clinical phenotype with referring physician
Autosomal recessive variants
Include heterozygous alleles as disease causing if:
• Truncating mutation (stop, abrogation of start or stop, obligatory splice, frameshift) or
• Missense mutation if any of following criteria were met:
• Predicted deleterious for the protein function (at least in two among three prediction
programs (Polyphen (>0.5), SIFT (Del.), Mutation taster (D.C.))
• Continuously conserved at least among vertebrates (or beyond)
• Previously reported as disease causing with functional evidence implicating mutation
causality
Exclude allele as disease causing if:
• Allele Frequency
• Allele frequency >0.1% (in EVS server, ExAC, gnomAD, 1000 genomes) unless functional
data exists to support the variant
• Non segregation
• if an affected family member is without the variant
• If an unaffected family member is with the allele consider incomplete penetrance and variable
expressivity
Discussion of genotype-phenotype correlation in a panel of nephro-geneticists followed by
review of clinical phenotype with referring physician
Autosomal dominant variants
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Supplementary Figure 3. Variant Criteria for Autosomal Recessive and Dominant Variant
Analysis
Supplementary Figure 4. Pedigree and DNA sequencing confirmation of mutations in NL
families.
A. Pedigree structures for two families UF26 and UF30 with SLC34A1 mutations.
B. Sanger sequencing tracing of SLC34A1 mutations in subjects.
Family numbers are shown on top, and cDNA change (c.) and protein sequence change (p.) are
shown below. Arrow heads indicate position of mutated nucleotide.
H, homozygous; h, heterozygous.
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Supplementary Figure 5. NA sequencing confirmation of mutations in NL singlets.
A. Sanger traces of SLC34A1 mutations in families URO11, URO12, URO13, URO17, URO29,
URO88, URO117,URO133, URO140, and URO169. Sanger trace of SLC34A1 variant of unknown
significance in URO131 is also shown.
B. Sanger traces of SLC4A1 mutations in subjects URO35, URO 178 and URO196.
C. Sanger traces of SLC7A9 mutations in subject URO152.
D. Sanger traces of APRT mutations in subject URO77.
Family numbers are shown on top, and cDNA change (c.) and protein sequence change (p.) are
shown below. Arrow heads indicate position of mutated nucleotide.




















Supplementary Figure 6. Genotype-Phenotype Correlation between Dominant SLC34A1 Alleles and Age of
Onset in Pakistani Stone Formers. Mutations were grouped by effect on protein coding and plotted versus age of
onset. Red bars indicate mean age of onset for each group with no trend noted. Mild missense mutations achieved
our minimal inclusion criteria, intermediate missense mutations additionally had conservation through invertebrates,






















































Supplementary Figure 7. Co-expression and plasma membrane localization of SLC34A1 wild-type
and mutated constructs. In panels A-G, EGFP-tagged WT SLC34A1 (encoding NaPiIIa) was co-
expressed with RFP-tagged SLC34A1 wild-type or mutated constructs based on Pakistani stone family
mutations in Opossum kidney cells. In A-G, EGFP- and RFP-tagged SLC34A1 constructs showed
appropriate trafficking and co-localization to the cell surface. In H and I, EGFP and RFP mock control










































































Supplemental Figure 8. Effect of Pakistani stone former SLC34A1 mutations on PO4 transport upon
co-expression with wildtype SLC34A1. Uptake of radioactively labeled phosphate was measured in
Xenopus laevis oocytes upon injection with either SLC34A1 wild-type (WT) RNA, 1:1 ratio of WT and
mutated SLC34A1 RNA and mutant constructs, 50% wild-type SLC34A1 RNA or water as a control. Level of
uptake was normalized as a percent of wild-type SLC34A1. The above histogram represents the mean of 3
experiments with standard error of the mean shown by error bars.
*Statistically significant difference (p<0.05) from Wildtype condition.
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